Cardiovascular Devices Market

SKU: DMMD4717 | Last Updated On: Aug 02 2022 | Available Formats

> Cardiovascular Devices Market Expected to reach at a high CAGR 6.8% by 2029: DataM Intelligence

Cardiovascular Devices Market is Segmented By Device Type (Diagnostic and Monitoring Devices, Electrocardiogram (ECG), Remote Cardiac Monitoring, Other, Therapeutic and Surgical Devices, Cardiac Assist Devices, Cardiac Rhythm Management Devices ), By Application(Coronary Heart Disease (CAD), Cardiac Arrhythmia, Heart Failure, Other), By End User(Hospitals, Specialty Clinics, Other)  and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029

Cardiovascular Devices Market size is projected to reach USD billion by 2029, with growth at a CAGR of 6.8% during the forecast period 2022-2029. Cardiovascular devices are used to diagnose heart disease and treat related health issues. The increasing prevalence of cardiovascular diseases and increasing technological advancements in cardiovascular devices are expected to drive this North America cardiovascular devices market growth. As per the research study, the global market is segmented by device type, application, end user, and by region. Based on region, the market is further divided into major countries such as USA, Canada, Brazil, Mexico, United Kinfdom, Germany, Spain, Italy, France, Russia, UAE, KSA, South Africa, Japan, China, India, Singapore, South Korea, Australia, and rest of the global countries.

Market Dynamics

The major factors driving the global cardiovascular devices market are the expected technological advancements to drive the market growth in the forecast period.

The technological advancements in cardiovascular devices are expected to drive the market growth  in the forecast period

Healthcare organizations worldwide have been transitioning to new business models to improve patient care and operational efficiencies. Artificial intelligence (AI), advanced algorithms, and predictive analytics are some of the recent advancements that aid in the early detection and treatment of critically ill patients and improve outcomes and provide value-based care. Then there's remote connected care, which allows electrocardiogram (ECG) diagnosis via cloud technology and bluetooth-enabled cardiac devices that measure the parameters and transmit them back to healthcare providers without the patient physically visiting the clinic. Over the last decade, technologies used to develop cardiology devices have advanced significantly, and indications for these devices have expanded. As a result, an increasing number of patients are being managed with cardiology devices, leading to exponential therapeutic and monitoring outcomes. Artificial intelligence is one such advancement that significantly impacts cardiology by improving diagnostic capabilities for certain heart conditions.

 For instance, on 12th October 2020, GE Healthcare received US FDA 510k clearance for its ultra-edition package of vivid cardiovascular ultrasound systems, including new artificial intelligence (AI)-based features that enable clinicians to acquire faster, more repeatable exams consistently.

The problems associated with cardiovascular devices is expected to hamper the market growth

Stringent regulatory policies are expected to be a major reason to hamper the growth of the cardiovascular devices market. Furthermore, if the devices do not meet the guidelines specified by regulatory authorities, they will not be approved for sale, resulting in a significant loss of investment for the manufacturers. When devices fail to meet USFDA criteria, there is a risk of device recall, which is particularly high in the case of cardiovascular devices, negatively impacting the market under consideration. For instance, on 24th February 2020, the USFDA issued a Class I recall for Abbott's NC Trek RX and NC Traveler RX Coronary Dilatation Catheters due to balloon deflation (diameters 4.0mm, 4.5mm, and 5.00mm).

COVID-19 Impact Analysis

The COVID-19 pandemic impacted cardiovascular device production in 2020. Furthermore, the postponement of elective procedures due to COVID-19-related measures has harmed the cardiovascular medical devices market, particularly in 2020. While some cardiovascular procedures are considered urgent, others have been postponed or delayed since the global pandemic. As a result, for some patients, lifestyle changes and medication can be prescribed instead of cardiovascular procedures. Another factor weighing on the market is a decrease in cardiovascular disease diagnosis due to healthcare resources being reserved for COVID-19 patients. As a result of the pandemic, many medical device companies have suffered losses in their cardiovascular devices business. Medtronic, for instance, announced a 33% reduction in its cardiac and vascular business sector in its 2020 outlook.

Cardiovascular Devices Market Scope

Metrics

Details

Market CAGR

6.8%

Segments Covered

By Device Type, By Application, By End User, and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America

To know more insights into Market, Get Our Sample Brochure

Segment Analysis

The ECG segment is expected to dominate the market growth in the forecast period

The adoption of the new generation of portable and compact ECGs is expected to drive market growth, particularly in the home healthcare segment. The prevalence of cardiovascular diseases (CVD) has increased, necessitating long-term ECG monitoring. Furthermore, with the introduction of wireless ECG, doctors can remotely monitor and diagnose the patient on time, further fueling the market. Cardiologs, an artificial intelligence (AI) cardiology diagnostics company, signed an exclusive distribution agreement with MicroPort CRM in France on 1st September 2020 to resell its cloud analysis solution for Holter ECGs.

Furthermore, among the new cardiac device technologies, wearable smart devices with heart-monitoring capabilities, such as bands, watches, and rings, are being used by many people worldwide. Fitbit received US FDA approval for its heart-monitoring electrocardiogram (EKG) app on Fitbit's new Sense smartwatch on 15th September 2020. The feature can monitor heart rhythms and detect atrial fibrillation, the most common type of irregular heartbeat. iRhythm, a digital healthcare company, launched its Zio system in the United Kingdom on 24th October 2019 to aid in identifying and clinical diagnosis of cardiac arrhythmias such as atrial fibrillation (AF). The Zio system consists of a small wearable heart monitor attached to the patient's chest for 14 days.

Geographical Analysis

North America region is expected to hold the largest market share in the global cardiovascular devices market

According to the American Heart Association Research Report 2018, heart disease kills one out of seven people in the United States. Coronary heart disease is the leading cause of death from cardiovascular disease in the United States (43.8 percent), followed by stroke (16.8 percent), heart failure (9.0 percent), high blood pressure (9.4 percent), artery diseases (3.1 percent), and other cardiovascular diseases (17.9 percent ). This factor is driving the market in the United States by increasing demand for better treatment with efficient medication.

Furthermore, a few of the country's key market players are developing novel products and technologies to compete with existing products, while others are acquiring and partnering with other companies trending in the market. Abbott restarted its LIFE-BTK clinical trial in September 2020 to assess the safety and efficacy of its new Esprit BTK Everolimus Eluting Resorbable Scaffold System.

Competitive Landscape

With mergers, collaborations, and product launches, the global cardiovascular devices market is highly competitive. Some of the key players in the market are Abbott Laboratories, Boston Scientific Corporation, Edwards Lifesciences, Cardinal Health Inc., Medtronic PLC, B. Braun Melsungen AG, Siemens Healthcare GmbH, Terumo Cardiovascular Systems Corporation, GE Healthcare

Medtronic PLC

Overview: Medtronic is a medical technology and services company. The Company develops, manufactures, and markets its medical devices and technologies to hospitals, physicians, clinicians, and patients in approximately 160 countries. The Company operates in four segments Cardiac and Vascular Group, Restorative Therapies Group, Minimally Invasive Technologies Group, and Diabetes Group. The company was founded in 1949.

Product Portfolio: Micra AV is the smallest pacemaker with atrioventricular (AV) synchrony, used to treat AV block patients.

Key Developments: On January 20th, The Micra AV, the world's smallest leadless pacemaker with atrioventricular (AV) synchrony, was approved by the US Food and Drug Administration (FDA).

Trending Topics

Automated External Defibrillator Market

Plaque Modification Devices Market

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report



Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!

linkedinpinterest